Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Reported by Yahoo Finance · Published 24 Aug 2026, 6:32 AM MYT (1 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery? 1 hr ago The next big oil trade may have nothing to do with oil stocks 1 hr ago Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? 1 hr ago The $70M business behind Ballerina Farm 1 hr ago Fast fashion giant Shein launches up to $1.8 billion Hong Kong IPO 1 hr ago Stock futures slip as U.S. and Canada appear headed for trade war 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Summary

More in Markets

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

The next big oil trade may have nothing to do with oil stocks

The $70M business behind Ballerina Farm

Stock futures slip as U.S. and Canada appear headed for trade war

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can